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Abstract 
Background: Epilepsy is the most common serious neurological condition yet, despite this, 
there is a dearth of information on its long-term prognosis, with few described cohorts having 
more than 10 years of follow-up. We report 25-year follow-up for one of these cohorts.  
Methods: The National General Practice Study of Epilepsy (NGPSE) is a prospective cohort 
study of people with newly diagnosed seizures. Of 1,012 people included in the study 792 
were classified as having epileptic seizures. We investigated seizure outcome and survival in 
this cohort. 
Findings: After excluding 13 people with missing epochs of seizure data, long-term follow-
up was obtained in 366, 76% of the 482 people still alive (mean follow-up 21·6 years). Of 
these, 303 (83%) were in 5-year terminal remission with 236 (64%) in terminal remission and 
off AED treatment. The proportion entering terminal remission seemed to increase with 
follow-up. For people who had only had a single seizure by five years from entry, the 
probability of remaining seizure-free 20 years later was 0·85 (95% CI 0·76, 0·90). The risk of 
premature mortality was, however, significantly increased in people who became seizure-free 
by the end of the first year of follow-up and who remained seizure-free throughout follow-up 
(SMR 1·6 (95% CI 1·4, 2·0).  
Interpretation: People with epilepsy in the community generally have a good prognosis for 
seizure control with prolonged follow-up. The risk of premature mortality is, however, 
significantly increased even in people with enduring seizure-freedom. It is paramount that 
reasons for this are identified. 
Funding:  
NIHR University College London Hospitals Biomedical Research Centre; Brain Research 
Trust; Epilepsy Society 
Introduction 
Epilepsy remains the most common serious neurological disorder, yet there is a dearth of 
information on long-term prognosis.
1
 Few studies have examined prognosis with more than 
ten years follow-up (Table 1). The UK National General Practice Study of Epilepsy (NGPSE) 
is a prospective cohort study of people with newly diagnosed seizures set up in 1984 to 
determine the prognosis of people with epilepsy and febrile seizures. The last reports on 
prognosis were at nine years follow-up.
2,3
 Long-term (24 years) follow-up on 220 children 
with febrile seizures has been reported,
4
 as well as long-term mortality to April 2009.
5
 We 
now provide a comprehensive review of the outcome of those with epileptic seizures up to 25 
years after study entry, including probability of seizure recurrence, remission, outcome after 
five and ten years, patterns of seizure recurrence and mortality. 
Methods 
The methodology of the NGPSE has been previously described.
6
 General practitioners (GPs) 
across the UK registered people with newly suspected seizures (including febrile seizures) 
between 1984 and 1987. At six months after registration, a diagnostic panel reviewed all 
1195 cases registered using all contemporaneous data available.
6
 A minority were excluded 
because of a prior diagnosis of epilepsy (104 (9%)) or an alternative diagnosis (79 (7%)). The 
remaining 1012 (85%) were classified as having definite (564 (47%)) or possible epilepsy 
(228 (19%)), or febrile seizures (220 (18%)). Follow-up used postal questionnaires sent to the 
individuals’ GPs approximately yearly until 1997, with further follow-up in 2001 and in 
2009-10.  
A complete description of the methodology of the NGPSE may be found as supplemental 
material online.  
Statistics 
The index seizure (IS) was the seizure which prompted the GP to consider a diagnosis of 
epilepsy and to register a person with the NGPSE. The number of seizures prior to the IS was 
estimated and grouped. The date of the first seizure after the IS was noted, as were the date of 
the first seizure occurring at least five years, and at least ten years, after the IS. The date of 
the last follow-up at which seizure status was recorded was taken as the end of follow-up for 
the analyses of seizure outcome. Actuarial analysis was used to investigate probability of 
seizure recurrence after the IS and after five years and ten years after the IS. Factors affecting 
seizure recurrence were determined using Cox regression, unless proportionality assumptions 
were not met, when the log rank test was used. For analysis of survival, the end of follow-up 
was death or 5
th
 October 2009, whichever occurred earlier. 
For each 12-month period since the IS, a dichotomous variable was calculated denoting the 
presence or absence of seizures during that 12-month period; no distinction was made 
between seizure types. Time to the completion of the first three-year and five-year remissions 
from the IS was noted, as well as terminal five-year remission, based on these data. Patterns 
of seizure outcome were described, with follow-up duration, using these dichotomous 
variables (table 2). The dichotomous variables were used to construct a graph illustrating the 
probability of being seizure-free each year stratified on seizure status in the preceding year. 
The Standardised Mortality Ratio (SMR) was calculated using the methods described 
previously
5
 for the whole cohort. Expected numbers of deaths were estimated using age, sex 
and calendar year-specific death rates in England and Wales.
7
 The SMR was calculated for 
people who became seizure-free by the second year and who remained seizure-free 
throughout follow-up; SMRs were calculated from the end of year 2 to October 2009, for 
years 3 to 10 of follow-up, and from year 11 to October 2009. An SMR was also calculated 
for people with a single notified seizure ever. All death certificates were examined for 
mention of epilepsy. 
Data were analysed using Stata v13 (Texas).  Differences between proportions were 
calculated using CIA software.
8
 
Ethics approval. The National Research Ethics Committee approved the on-going follow-up 
of the cohort in November 2007 (REC Reference 07/H0720/160). 
 
Results 
Last follow-up 
For the whole cohort of 792 people with epileptic seizures, the mean duration of follow-up 
(to death or last follow-up) from the IS was 16·0 years (SD 8·8, median 16·5 years, range 0 
to 26·3 years); 302 people (38%) died by 5
th
 October 2009. For those alive (N=490) at this 
time, mean duration of follow-up was 21·6 years (SD 4·9, median 23·7 years). During 
follow-up, 69 (9%) had epochs when we did not know their seizure status although we have 
later follow-up information. Thirteen individuals with more than five years missing data were 
excluded from the remaining analyses which are based on a cohort of 779 individuals. 
In this cohort of 779 people, mean duration of follow-up from the IS was 16 years (SD 9, 
median 17 years); 297 of these died. Follow-up was obtained in 2009/2010 for 366 people 
(76% of those alive). For the 482 people alive in 2009, mean duration of follow-up was 22 
years (SD 5, median 24 years). 
Probability of seizure recurrence after the IS 
The IS was the first seizure in 397 people (51% of the cohort) and in one person this was 
undetermined. Seizures recurred in 473 people (60·7%), and were more likely to recur in 
those with seizures before the IS (HR 1·48, 95% CI 1·23, 1·77) but neither gender (HR 1·06, 
95% CI 0·89, 1·27) nor age at the IS (HR 1·00, 95% CI 0·99, 1·00) significantly affected 
probability of recurrence. Of 381 people with seizures before the IS, 293 (77%) had 1 to 5 
previous seizures, 53 (14%) had 6 to 10 previous seizures, and 35 (9%) had more than ten 
previous seizures. Compared with those with no previous seizures, those with more previous 
seizures were increasingly likely to have recurrences (HR 1·34, 95% CI 1·10, 1·63 with 1 to 
5 previous seizures, HR 1·69, 95% CI 1·19, 2·38 with 6 to 10 previous seizures, and HR 
3·29, 95% CI 2·24, 4·83 with more than ten previous seizures).  
Table 2 shows the probability of continued seizure-freedom at various time points.  
Remission 
Of 696 people with follow-up beyond the first year, 514 (74%) went into one-year remission 
in the second year. Of 502 with further follow-up, 333 (66%) stayed in remission until last 
follow-up one to 24 years later. 
Of 664 people with follow-up to three years, 594 (89%) achieved a three-year period of 
remission, with probability 0·71 (95% CI 0·68, 0·75) by five years, 0·88 (95% CI 0·85, 0·90) 
by 10 years and 0·91 (95% CI 0·89, 0·94) by 15 years. 
Of 639 people with follow-up to five years, 541 (85%) achieved 5-year remission, with 
probability 0·41 (95% CI 0·38, 0·45) by five years, 0·78 (95% CI 0·74, 0·81) by ten years, 
and 0·85 (95% CI 0·82, 0·88) by 15 years. 
In those with follow-up to five years, 487 of 639 people (76%) were in five-year terminal 
remission at the end of follow-up. Of those not followed to 2009/2010 (because of death or 
loss to follow-up) 184 of 273 people (67%) were in five-year terminal remission at last 
notification. In those with complete follow-up to 2009/2010, 303 of 366 people (83%) were 
in 5-year terminal remission, of whom 236 (78%) were off AEDs. Six people had seizures in 
the previous five years but were not taking AEDs, and 67 people (18%) took AEDs but had 
had no seizures in the previous five years. Of 273 people without follow-up to 2009/2010, 
159 (58%) had died by October 2009, of whom 99 (62%) were in terminal remission when 
last followed-up. 
Of 215 children (aged less than 16 at the IS) with five or more years of follow-up, 174 (81%) 
were in five-year terminal remission at last follow-up, compared with 313 of 424 (74%) of 
adults (difference 7·1%, 95% CI 0·11, 13·5%). These figures were 137 of 163 (84%) children 
and 166 of 203 (82%) adults with complete follow-up (difference 2·3%, 95% CI -5·7, 9·9%). 
Outcome after 5-years 
The 639 people with at least five years of follow-up were divided into four seizure pattern 
groups depending on seizure status prior to the IS and during the first five years of follow-up; 
four people had missing data. Of the other 635, 153 people (24%) had no seizures before the 
IS or during the first five years of follow-up, 151 (24%) had no seizures before the IS, but 
had seizures during the first five years , 111 (17%) had seizures before the IS but not since, 
and 220 (35%) had seizures before and after the IS. The log rank test indicated a significant 
difference in probability of seizure recurrence among the groups (p<0·0001) (figure 2); the 
log rank test showed a higher probability of recurrence in the two groups with seizures in the 
first five years than in the other two groups (Χ2 88·7, p < 0·0001), but there were no 
differences between the two groups without seizures in the first five years (Χ2 2·11, p = 
0·15), or between the two groups with seizures (Χ2 1·47, p = 0·22). By 25 years, the 
probability of remaining seizure-free was 0·85 (95% CI 0·76, 0·90) in those with a single 
seizure at five years, 0·76 (95% CI 0·65, 0·85) in those with seizures only before the IS, 0·51 
(95% CI 0·42, 0·59) for those with seizures only in the first five years, and 0·43 (95% CI 
0·35, 0·51) in those with seizures during both time periods. 
Seizure Patterns 
Patterns of seizure outcome are illustrated in table 3. In those with no missing data , 52% 
(359/684) were seizure-free during the first year of follow-up. This increased to 75% by the 
second year, to 78% by the third year, and was consistently over 80% by the fifth year of 
follow-up, although it was not always the same people who were seizure-free. The proportion 
who were seizure-free one year and relapsed the following year was small (<8%) but never 
decreased to zero. Figure 3 shows the probability of being seizure-free in any year stratified 
on seizure status in the previous year.  
Seizure outcome, stratified on seizure status in the previous five years at five and at ten years 
is illustrated in figure 4.  
Mortality 
In the whole cohort of 792 people, 302 had died by October 2009 (SMR 2·19, 95% CI 1·96, 
2·45); epilepsy was mentioned on the death certificates of 20 (6·6%). 
By the beginning of the second year of follow-up, 343 people were seizure-free and had no 
further recorded seizures; ten of these had no seizure follow-up beyond the second year. Of 
these, 107 people had died by October 2009 compared with 64·9 expected; SMR 1·65 (95% 
CI 1·36, 1·99). The SMR appeared similar in males (SMR 1·75, 95% CI 1·35, 2·27) and 
females (SMR 1·55, 95% CI 1·18, 2·04). Between years 2 and 10 of follow-up, 52 people 
died (29·6 expected; SMR 1·76, 95% CI 1·34, 2·31). From the end of year 10 to October 
2009, 55 people died (35·3 expected; SMR 1·56, 95% CI 1·20, 2·03). The SMR in 149 
people with a single notified seizure and with follow-up for more than one year, was 1·60 
(95% CI 1·22, 2·11) (1·63 in males and 1·57 in females). Most (123/149, 83%) had at least 
ten years of follow-up. 
Discussion 
The NGPSE was set up as a pragmatic, observational study in the 1980s and aimed to follow 
a cohort of people of all ages with newly diagnosed seizures, of any type, over many years to 
establish long-term prognosis. 
Overall the reported percentages of people in terminal remission in previously reported 
studies (table 1) range between about 44 and 70.
9-15
 Our results are somewhat higher than 
these figures (83% in 5-year terminal remission in people with follow-up to 2009/2010; 67% 
in those with shorter follow-up). This may be influenced by the long period of follow-up in 
this study, with the proportion of people seizure-free consistently greater than 80% after five 
years follow-up. This finding that the number of people in terminal remission increases with 
longer follow-up was previously suggested in two smaller cohort studies. In the Rochester 
cohort 61% of the cohort was in terminal remission at 10 years and 70% at 20 years,
9
 while in 
the Finnish study 48% were in terminal remission at ten years, 56% at 20 years, 60% at 30 
years and 70% at 40 years follow-up.
16
 
The high proportion with terminal remission seen in the NGPSE may, in part, be explained 
by the inclusion of people with single seizures who would be expected to have a lower risk of 
seizure recurrence than people with two or more seizures(Table 2); the Finnish and Rochester 
cohorts
17,18
 did not include people with single seizures, and almost half of the Finnish cohort 
also had learning disability.
19
 Similarly the inclusion of people with acute symptomatic 
seizures is likely to have favourably influenced the outcome. In a study comparing outcomes 
in people with stroke, brain injury or CNS infection who had a single unprovoked seizure or a 
first acute symptomatic seizure, the risk of a subsequent unprovoked seizure was significantly 
higher in people with a first unprovoked seizure (64·8%; 95% CI: 55·1, 74·4) than in people 
with acute symptomatic seizures (18·7%; 95% CI: 13·7, 25·4).
20
 
Looking at specific seizure patterns (table 3), the largest group (34%) remained seizure-free 
since the IS while 18% entered terminal remission after initial seizures. Only eight percent 
had no year of seizure-freedom although this group had a shorter follow-up (median 1·6 
years) than the other seizure pattern groups (median follow-up 12·2 to 23·9 years), probably 
because people died or were lost to follow-up before an alternative seizure pattern was 
established. The remaining 35% with follow-up data had a more complex pattern of seizures, 
with two-thirds of these seizure-free at last follow-up.  
This study demonstrates that the longer an individual has had only a single seizure, the less 
likely the risk of a seizure recurrence. Nevertheless the risk of a further seizure never 
completely disappears (Table 2, Figure 2) although the risk is small. 
The number of seizures prior to the IS was predictive of the probability of seizure recurrence 
after the IS, but the presence of seizures in the first five years after the IS seems more 
important in seizure prognosis. In the same cohort, it was previously shown that the number 
of seizures during the first six months after presentation was the most important predictor of 
remission.
3
 
The probability of becoming seizure-free becomes more remote the longer seizures persist; 
the probability of being seizure-free during the next ten years was 0·50 in those with seizures 
in the first five years but only 0·36 in those with seizures in years 6 to 10. Encouragingly the 
proportion of people who become seizure-free and then subsequently relapse is small 
(probability of relapse in the subsequent 10 years was 0·14 in those seizure-free in the first 
five years and 0·08 in those seizure-free in the second five years) (Table 3).   
We have shown that the seizure prognosis for most people with epilepsy in the general 
population is good, with over 80% in remission for most of follow-up. We previously 
showed, however, in this cohort that the risk of premature mortality is increased throughout 
prolonged follow-up.
5
 We have now shown that the SMR is significantly raised in people 
who had no seizures after the first year after the IS and that it is also raised in people who 
only have a single recorded seizure. Thus, although overall seizure prognosis is good, the 
prognosis for survival is less good, even amongst those whose seizures have ceased, and the 
reasons for this are unknown. An early study from the US found the SMR to be 2·3 in 159 
people with a single seizure.
21
 In other studies which report survival after an initial isolated 
seizure, it is not clear how many people remained seizure-free.
22,23
 It is also of interest that 
only 6·6% (20/302) of those who died had epilepsy mentioned on the death certificate. It 
seems that people with a predisposition to seizures also have a predisposition to other 
morbidities,
24
 as previously suggested
 
and that these co-morbidities constitute a major factor 
in premature mortality, particularly in people in long-term remission. This needs thorough 
investigation to allow for preventable strategies to be deployed. 
Our study has limitations. During a long-term, observational study it is inevitable that some 
people are lost to follow-up, either for a short time or until the end of the study. Survival 
analysis assumes that any right censoring (loss to follow-up) is independent of survival, but it 
is possible that those who were not followed-up were in some way different from those who 
were. Our information came via GPs, and during a study of this duration some GPs changed; 
it is possible that some individuals did not notify their GP of all seizures, or that they were 
not noted in the medical records. 
The NGPSE is likely to be one of the last large cohort studies of people with epilepsy where 
inclusion is determined by the presenting symptom. The perception of epilepsy as a 
homogeneous entity is being replaced by the concept of it being a collection of genetic and 
acquired conditions with a propensity to have unprovoked seizures. Consequently future 
cohort studies in people with epilepsy are likely to be smaller, determined by aetiology (for 
example a genetic variant), which will allow for greater prognostic accuracy (in terms of both 
seizure control and survival) of people with the individual epileptic syndromes.   
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Table 1: Studies of the long-term (>5 years) prognosis of epilepsy 
Study Study  
Design (country) 
Number 
in cohort 
Subject 
age at 
baseline 
(years) 
Follow-up 
(years) 
Seizure prognosis Mortality 
     5-year 
remission (%) 
5-year 
terminal 
remission (%) 
5-year 
terminal 
remission off 
AEDs (%) 
Standardiz
ed 
mortality 
ratio 
(95%CI) 
Annegers 
19799 
Prospective 
community-
based cohort 
(USA) 
457 NR 5 to ≥ 20 
(from 
epilepsy 
diagnosis) 
76 70 (at 20 
years) 
50 (at 20 
years) 
NR 
Brorson 
198710  
Prospective 
community-
based cohort 
(Sweden) 
194 ≤ 19 12 (from 
study 
enrolment)  
NR 64 (3-year 
terminal 
remission) 
40% (3-year 
terminal 
remission) 
NR 
Carpio 
2005a25 
Prospective 
population-based 
cohort (Parsis, 
India) 
104 45 
(median) 
14 (from 
study 
enrolment) 
NR NR NR 0·8 (0·5, 
1·0)a 
Carpio 
2005b25 
Prospective 
population-based 
cohort (Vasai, 
India) 
51 23 
(median) 
10 (from 
study 
enrolment) 
NR NR NR 3·9 
Ding 201326 Prospective 
community-
based cohort 
(China) 
1986 33 
(mean) 
6·4 (from 
study 
enrolment) 
NR NR NR 2·9 (2·6, 
3·4) 
Hauser 
198021 
Prospective 
population-based 
cohort (USA) 
618 NR 29 (mean, 
from study 
enrolment) 
NR NR NR 2·3 (1·9, 
2·6) 
Lindsten 
200027, 
200111 
Prospective 
population-based 
cohort (Sweden) 
89 ≥ 17  9-11 (from 
epilepsy 
diagnosis) 
58 58 NR 2·5 (1·2, 
3·2) 
Nicoletti 
200912 
Prospective 
population-based 
cohort (Bolivia) 
103 (71 
for 
remission
) 
18·6 
(mean) 
10 (from 
study 
enrolment) 
NR 44 39b 1·3 (0·7–
2·4) 
Olafsson 
199823 
Prospective 
population-based 
224 NR 32-36 
(from 
epilepsy 
NR NR NR 1·6 (1·2, 
2·1) 
cohort (Iceland) diagnosis) 
Sillanpää 
200613 
Prospective 
population-based 
cohort (Finland) 
144 < 16 40 (median 
from study 
enrolment) 
81 67 58 NR 
Surrmeijer 
199114 
Prospective 
community-
based cohort 
(Netherlands) 
112 10-12 5 (from 
study 
enrolment) 
NR 64 NR NR 
Wakamoto 
200015 
Prospective 
population-based 
cohort (Japan) 
148 <16 6-38  63 55  
Earlier analyses of the National General Practice Study of Epilepsy cohort 
 
Cockerell 
199528, 
Neligan 
2011
5
 
Prospective 
community-
based cohort 
(UK)a 
792 all 7·1 (for 
remission) 
23 (for 
mortality) 
Both 
reported as 
medians, 
from study 
enrolment 
71 (at 9 years) 57 (at 9 
years) 
NR 2·2 (2·0, 
2·5) 
Legend: AEDs – antiepileptic drugs 
a
 There were considerable issues in defining age-specific mortality rates for the general 
population in this study which may in part explain an SMR which is very different from most 
others published 
b
 This estimate is based upon a sample where 23·7% (22/93) of participants were lost to 
follow up 
Legend: AEDs – antiepileptic drugs 
  
Table 2.  Probability (95%CI) of remaining seizure-free after various periods from the IS, 
after a single seizure by five years and after a single seizure by ten years. 
 
Outcome Whole group 
(n=779) 
No seizures 
prior to IS 
(N=397) 
Seizures 
before the IS 
(N=381) 
Single seizure 
by 5 years 
(N=153) 
Single seizure 
by 10 years 
(N=130) 
Seizure-free at 
5 years 
0·41  
(0·37, 0·44) 
0·48  
(0·43, 0·53) 
0·34  
(0·29, 0·38) 
  
Seizure-free at 
10 years 
0·37  
(0·33, 0·41) 
0·44  
(0·39, 0·50) 
0·30  
(0·25, 0·35) 
0·92  
(0·86, 0·95) 
 
Seizure-free at 
15 years 
0·35  
(0·32, 0·39) 
0·43  
(0·38, 0·48) 
0·28  
(0·23, 0·32) 
0·89  
(0·82, 0·93) 
0·97  
(0·92, 0·99) 
Seizure-free at 
20 years 
0·35  
(0·31, 0·39) 
0·43  
(0·38, 0·48) 
0·27  
(0·23, 0·32) 
0·89  
(0·82, 0·93) 
0·97  
(0·92, 0·99) 
Seizure-free at 
25 years 
0·33  
(0·29, 0·37) 
0·41  
(0·35, 0·46) 
0·26  
(0·21, 0·31) 
0·85  
(0·76, 0·90) 
0·92  
(0·84, 0·96) 
 
 
 
 
 
 
 
 
 
Table 3: Patterns of seizure outcome in those with fewer than five years of ‘gaps’ in their 
follow-up data, based on dichotomous seizure variables (N=779) 
Pattern N Years of follow-up 
(Median (range) 
Died in first year  34 (4%)  
Always seizure-free apart from IS  267 (34%) 22·2 (<1 to 25) 
No year of seizure-freedom 62 (8%) 1·6 (<1 to 25) 
Initial seizure free year(s) followed by seizures  12 (2%) 13·6 (2 to 25) 
Initial year(s) with seizures, followed by seizure-freedom 142 (18%) 22·5 (1 to 26) 
Initially & finally seizure-free year(s), but with one period of 
seizures intervening 
62 (8%) 19·7 (3 to 25) 
Initially and finally year(s) with seizures, but with one period 
of seizure-freedom intervening 
21 (3%) 12·2 (2 to 25) 
Complex pattern, but with terminal seizure-freedom 117 (15%) 22·8 (5 to 25) 
Complex pattern with seizures at the end of follow-up 57 (7%) 23·9 (4 to 26) 
No follow-up 5 (<1%)  
 
 
  
Figure 1. Study profile 
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Figure 2.  Probability of seizure recurrence after the first five years of follow-up 
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 Figure 3. Follow-up stratified on presence or absence of seizures in the previous year 
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Figure 4. Seizure recurrence after five and ten years stratified by seizure status in the previous five years 
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Systematic review 
We searched Ovid Medline (1975 to March 27, 2014), without any language restrictions, 
using MeSH subject headings and the following search strategy: “exp epilepsy/ AND exp 
cohort studies/ AND (exp prognosis/ OR exp/mortality)”. We also manually reviewed the 
bibliographies of three recent narrative reviews
1-3
 as well as the bibliographies of included 
studies for additional references. Our initial search resulted in 2590 de-duplicated titles and 
abstracts which were screened by one study author (MRK), of which the full text of 42 were 
reviewed in addition to another 10 which were identified with manual searching. Amongst 
these we identified 13 studies (14 articles, four of which reported on only two studies
4-7
, 
reporting prognosis and mortality in separate papers, and one of which reported two different 
studies
8
) reporting data on long-term seizure remission and/or mortality in unselected 
population or community-based cohorts of people with epilepsy followed for at least five 
years. The study characteristics and findings are presented in table 1. Two of the articles 
identified represented earlier analyses of the National General Practice Study of Epilepsy 
(NGPSE) cohort.
4, 5
 Of the remaining studies, only two had sample sizes greater than 250, 
one of which had a follow-up period of only 6·4 years.
9, 10
 Three studies reported 5-year 
epilepsy remissions of 58%, 76% and 81%
9, 11
, five studies reported 5-year terminal 
remissions of 44% to 70%
7, 9, 11-13
 and five studies reported 5-year terminal remissions off 
AED treatment of 39% to 58%.
9, 11, 12, 14
 Seven studies reported an overall standardized 
mortality ratio (SMR), ranging from 0·76 to 3·9.
6, 8, 10, 12, 15, 16
  
 
Interpretation 
Besides the National General Practice Study of Epilepsy (NGPSE), there are only two other 
population or community-based studies with a longitudinal cohort larger than 250 subjects, 
only one of which one has a follow-up period greater than 10 years. After a mean follow-up 
of 21·6 years among the 366 for whom we had complete follow-up data and had not died, we 
found 303 (83%) were in 5-year terminal remission and 236 (64%) in terminal remission off 
AED treatment. The NGPSE’s probability of terminal remission is higher than most other 
studies which may reflect the long period of follow-up as well as our inclusion of individuals 
with a single unprovoked or symptomatic seizures. In the NGPSE, the proportion entering 
terminal remission seems to increase with duration of follow-up (83% in people with follow-
up to 2009/2010, 67% in those whose most recent follow-up was earlier). For people who had 
only had a single seizure by five years from entry, the probability of remaining seizure-free 
20 years later was 85%. Our group has previously reported that the risk of premature 
mortality is elevated among individuals with epilepsy relative to the general population. The 
present submission provides new, previously unpublished, analyses that suggests that this risk 
of premature mortality is also significantly increased in people who became seizure-free by 
the end of the first year of follow-up and who remained seizure-free throughout follow-up 
(Standardized mortality ratio 1·6).  
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